Mechanisms of Platelet Aggregation Disturbances and Their Relation to Treatment in Patients with Chronic Uremia

Komarnicki, M; Pietrzak, I

doi:10.1177/039139888801100206

Cited by 7 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Activated platelets release ADP, serotonin, and other factors that maintain their stimulation. As a consequence, platelets are becoming 'exhausted' and ex hibit in in vitro experiments signs of acquired storage pool disease [6][7][8],…”

Section: Discussionmentioning

confidence: 99%

Dialyzable Factors from Uremic Serum Increase <sup>125</sup>I-Fibrinogen Binding by Normal Blood Platelets

Komarnicki¹,

Krupa²,

Kaźmierczak³

et al. 1990

Nephron

Self Cite

View full text Add to dashboard Cite

The influence of uremic serum on ¹²⁵I-fibrinogen binding by normal blood platelets after induction with adenosine diphosphate was evaluated. The study was performed on 12 hemodialyzed uremic patients. The control group included 12 healthy subjects. It has been demonstrated that the uremic serum from the patients before hemodialysis significantly augmented fibrinogen binding by normal blood platelets (33.8 ± 11.8%) in comparison with control subjects (14.4 ± 8.9%). After hemodialysis, fibrinogen binding was comparable with the control group (14.9 ± 10.1%). Uremic toxins removable during hemodialysis are probably responsible for the potentiation of ¹²⁵I-fibrinogen binding by platelets.

show abstract

Section: Discussionmentioning

confidence: 99%

Dialyzable Factors from Uremic Serum Increase <sup>125</sup>I-Fibrinogen Binding by Normal Blood Platelets

Komarnicki¹,

Krupa²,

Kaźmierczak³

et al. 1990

Nephron

Self Cite

View full text Add to dashboard Cite

show abstract

“…As could be shown, for example, after ingestion of ASA, as well as in the case of patients with myeloproliferative syndromes, uremia and known hereditary platelet deficiencies, hypoaggregability can be reliably detected. Hypoaggregability is a well-known occurrence in myeloproliferative syndromes [6,9], ure mia [10][11][12] and other illnesses, but not enough is known about its progress and sus ceptibility.…”

Section: Discussionmentioning

confidence: 99%

Attempts to Standardize Platelet Aggregation Measurements: Simplified Screening Tests

Kirchhof

Kirchhof²,

Etscheid³

1990

Pathophysiol Haemos Thromb

View full text Add to dashboard Cite

We present a standardized measurement of collagen and ADP-induced platelet aggregation with the help of a personal computer. The calculator improves the recording of measurements and the automatic calculation of parameters to define the strength of aggregation in various aggregation phases, as well as aggregation and disaggregation velocities. The dose-effect relationships between aggregants and five calculated parameters after addition of ADP and four after addition of collagen are demonstrated in the light of measurements taken in 40 healthy persons. Comparison of these measurements with those of 8 volunteers 24 h after they had taken 250 mg of acetylsalicylic acid and those of 5 patients with typical illnesses associated with hypo- and hyperaggregability shows that analysis of the aggregation with two reagent concentrations (1,2 and 4 μg/ml collagen, 1, 2 and 4 μmol/ml ADP) and the resulting values allow one to distinguish between normal, hypo- and hyperaggregable platelets.

show abstract

“…Reduced quantity of such platelets in hemodialyzed patients is probably one of the factors responsible for the depressed platelet aggregation induced by ADP and other agonist [2,4]. …”

Section: Discussionmentioning

confidence: 99%

Mepacrine-Labeled Platelet Dense-Body Number in Patients with Chronic Uremia

Komarnicki¹,

Pietrzak²,

Zozulińska³

1988

Nephron

Self Cite

View full text Add to dashboard Cite

Dense bodies are platelet organelles that store adenosine diphosphate. We have estimated the number of platelet dense bodies in patients with chronic uremia treated conservatively, by peritoneal dialysis and by hemodialysis. All groups of patients and control subjects were found to have similar mean numbers of platelet dense granules. Analysis of platelet distribution according to number of dense bodies has shown that patients undergoing hemodialysis have a decreased percent of platelets with a greater number of granules.

show abstract

Mechanisms of Platelet Aggregation Disturbances and Their Relation to Treatment in Patients with Chronic Uremia

Cited by 7 publications

References 12 publications

Dialyzable Factors from Uremic Serum Increase <sup>125</sup>I-Fibrinogen Binding by Normal Blood Platelets

Dialyzable Factors from Uremic Serum Increase <sup>125</sup>I-Fibrinogen Binding by Normal Blood Platelets

Attempts to Standardize Platelet Aggregation Measurements: Simplified Screening Tests

Mepacrine-Labeled Platelet Dense-Body Number in Patients with Chronic Uremia

Contact Info

Product

Resources

About